"...compared to other global pharmaceutical stocks still value, especially with yet another blockbuster on the horizon."
Still value?
Compared to other global pharmaceutical stocks?
Wow.
CSL is currently being valued in excess of 30x P/E and more than 20x EV/EBITDA.
If that represents "value", then I shudder to think what the valuations of those other global pharmaceutical stocks must look like.
I love CSL, but I sure as heck wouldn't be buying shares in the company at the current price level.
Ann: Half Year Results Analyst Presentation, page-173
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$308.56 |
Change
1.960(0.64%) |
Mkt cap ! $149.1B | |||
| Open | High | Low | Value | Volume |
| $308.93 | $311.00 | $306.28 | $198.7M | 643.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 859 | $308.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $308.65 | 5 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |